You are here: Industry Insights > DSMB

News List

Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients prnewswire
August 04, 2021
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients.
Edesa Biotech to continue global Covid-19 drug trial pharmaceutical-technology
June 22, 2021
Edesa Biotech is set to continue Phase II/III clinical study of its drug candidate, EB05, to treat patients hospitalised with Covid-19 on receiving an independent Data and Safety Monitoring Board’s (DSMB) recommendation.
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue prnewswire
April 12, 2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a unanimous ...
AstraZeneca confirms COVID-19 vaccine efficacy with primary analysis europeanpharmaceuticalreview
March 29, 2021
Following DSMB concerns about the data released regarding the Phase III US trial, AstraZeneca has now confirmed that its vaccine is 76 percent effective against symptomatic COVID-19.
Could viral vector shortages disrupt the COVID-19 vaccine roll-out? europeanpharmaceuticalreview
March 26, 2021
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
NIAID statement on AstraZeneca vaccine and AstraZeneca update worldpharmanews
March 24, 2021
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.
US health agency questions AstraZeneca’s Covid-19 vaccine trial data pharmaceutical-technology
March 24, 2021
US health officials have questioned the validity of AstraZeneca’s most recent vaccine trial results, saying the data provided by the company may be “outdated”.
NIH pauses Covid-19 convalescent plasma trial pharmaceutical-technology
March 04, 2021
The US National Institutes of Health (NIH) has put on hold a trial of convalescent blood plasma in treating patients with mild-to-moderate Covid-19 symptoms as the study provided no significant benefit in this group.
RedHill Biopharma Announces Positive DSMB Review for Phase 2/3 COVID-19 Study of Opaganib americanpharmaceuticalreview
February 04, 2021
RedHill Biopharma announced the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of ...
Dr. Reddy’s receives approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India pharmaceutical-business-review
January 20, 2021
Dr. Reddy’s Laboratories has announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.

Previous page 1 2 Next page